INTRODUCTION AND OBJECTIVES:
No reliable biomarker is available for predicting worse clinical outcome in chemo-resistant urothelial carcinoma (UC) patients treated with pembrolizumab. We focused on the neutrophil-lymphocyte ratio (NLR), which is reported to be a simple index of systemic inflammation and a possible biomarker for predicting prognosis in various malignancies, including UC. Our aim was to evaluate whether a high pretreatment NLR level (pre-NLR) could predict subsequent clinical outcomes in chemoresistant UC patients treated with pembrolizumab.
METHODS: We identified 50 cases treated with pembrolizumab for chemo-resistant UC between December 2017 and August 2018 at our 5 institutions. We investigated the association between pre-NLR levels and their prognosis. We defined patients with NLR of >3.90 as the high pre-NLR group according to a calculation by receiveroperating curve analysis.
RESULTS: The high pre-NLR group consisted of 13 cases (26.0%). In the 45 cases who had measurable lesions, at the point of maximum effect the sum of the target lesion longest diameter (SLD) was decreased in 17 cases (37.8%) compared to baseline. SLD was decreased in 2 cases (15.4%) in the high pre-NLR group, which was significantly lower than that in the low pre-NLR group (15 cases, 46.9%, p[0.048) . The disease control rate defined by RECIST ver. 1.1 at best response in the high pre-NLR group was 15.4%, which was significantly lower than that in their counterpart (45.9%, p[0.049) . No association was observed between pre-NLR levels and the occurrence of adverse events. The 6-month progression-free survival (PFS) rate for the high pre-NLR group was 10.3AE9.4%, which was significantly lower than that for their counterpart (31.9AE9.2%, p[0.001). Multivariate Cox regression analysis revealed that pre-NLR level was the only independent indicator for disease progression (p[0.004). Furthermore, the 6-month cancer-specific survival (CSS) rate for the high pre-NLR group (53.7AE15.7%) was significantly lower than that for their counterpart (90.0AE6.7%, p<0.001). Multivariate analysis revealed that an elevated pre-NLR was the only independent indicator for cancer-specific death (p[0.007). The change of NLR level before and after pembrolizumab was elevated in 28 cases (56.0%). However, there was no association between clinical outcome of PFS and CSS and the change of NLR level.
CONCLUSIONS: Elevated pre-NLR could identify a population with a poor response to pembrolizumab treatment among chemoresistant UC patients.
Source of Funding: none

MP26-02 CAN WE PREDICT PT0 AFTER NAC IN PTS WITH MIBC? A CHALLENGE OF OPTIMAL CANDIDATE SELECTION FOR BLADDER PRESERVATION THERAPY
Hirotaka Horiguchi*, Shingo Hatakeyama, Hayato Yamamoto, Atsushi Imai, Takahiro Yoneyama, Yasuhiro Hashimoto, Hirosaki, Japan; Takuya Koie, Gifu, Japan; Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: A platinum-based neoadjuvant chemotherapy (NAC) is being established as standard therapy for muscle invasive bladder cancer (MIBC). However, the prediction of pT0 disease after NAC and optimal candidate selection for bladder preservation therapy remain challenging. We retrospectively examined whether clinical parameters could predict pT0 on radical cystectomy (RC).
METHODS: Between March 2005 and June 2018, we performed platinum-based neoadjuvant chemotherapy followed by radical cystectomy in 254 patients with T2-4NxM0 MIBC. After diagnostic transurethral resection of bladder tumor (TURBT), all participants received two courses of gemcitabine plus cisplatin (GCis) or gemcitabine plus carboplatin (GCb) based on cisplatin eligibility. Quantitative radiologic response was defined by RECIST ver. 1.1 using contrast enhanced computed tomography (CT). RC and bilateral pelvic lymphadenectomy were performed approximately within 90 days after initial diagnosis of MIBC. Multivariate logistic regression analysis was applied to develop the nomogram for pT0 prediction.
RESULTS: Median age and follow-up periods were 68 years and 50 months, respectively. Number of patients with GCis and GCb were 57 (22%) and 197 (78%), respectively. Of 254, 24 (9.5%), 89 (35%), 69 (27), and 7 (2.7%) patients achieved radiologic complete response (CR), partial response (PR), stable disease (SD), and progression disease (PD), respectively. In addition, 65 (26%) patients who underwent complete TURBT (cTURBT) remain undetectable tumor after NAC. We considered 89 patients with CR þ cTURBT (CR group) were potential candidate for bladder preservation therapy. After RC, 65 (26%) patients achieved pT0. The pT0 rate in CR, PR, SD and PD groups were 51%, 52%, 17%, 7.2%, and 0%, respectively. Multivariate logistic regression analysis showed that male, orthotopic ileal neobladder reconstruction, CR group were significant factor for pT0. The nomogram for predicting pT0 probability showed significant association with actual pT0 rate (c-index [ 0.812).
CONCLUSIONS: Although CR group significantly contributed to pT0 rate, residual tumor remains in half of patients with CR after NAC. Careful selection for bladder preservation therapy is necessary to avoid under treatment and/or overtreatment in patients with CR after NAC.
Source of Funding: none
MP26-03 CONTEMPORARY ANALYSIS OF URETEROENTERIC STRICTURES AFTER OPEN AND ROBOT-ASSISTED RADICAL CYSTECTOMY: A POPULATION-BASED STUDY
Alvin Goh, Neal Patel*, NY, NY; Art Sedrakyan, NY, NM; Andre Belarmino, Tianyi Sun, Bernard Bochner, Jim C. Hu, NY, NY INTRODUCTION AND OBJECTIVES: Robot-assisted radical cystectomy (RARC) has been shown to have comparable oncologic efficacy compared to open radical cystectomy (ORC). However, due to differences in surgical approach the incidence of benign ureteroenteric strictures may differ. We sought to compare the rates of benign strictures after RARC and ORC using a population-based data.
METHODS: From Surveillance, Epidemiology, and End Results (SEER)-Medicare, we identified 332 RARC and 1449 ORC performed during 2009 and 2014, using International Classification of Diseases-9th edition and Current Procedural Terminology 4th edition to compare the development of ureteroenteric strictures at 6 months, 1 year and 2 years following radical cystectomy. We defined ureteroenteric stricture as the need for procedural intervention, consistent with prior studies.
